Therapeutic effect of ghrelin in the course of cerulein-induced acute pancreatitis in rats.
Recent studies have shown that pretreatment with ghrelin exhibits protective effect in the gut. Administration of ghrelin reduces gastric mucosal damage, as well as inhibits the development of experimental pancreatitis. However, this protective effect requires administration of ghrelin before gastric or pancreatic damage and thus has a limited clinical value. The aim of present study was to assess the influence of ghrelin administered after development of acute pancreatitis on the course of this disease. Acute pancreatitis was induced by cerulein. Ghrelin was administered twice a day for 1, 2, 4, 6 or 9 days at the dose of 4, 8 or 16 nmol/kg/dose. The first dose of ghrelin was given 24 hours after last injection of cerulein. The severity of acute pancreatitis was assessed between 0 h and 10 days after cessation of cerulein administration. Administration of caerulein led to the development of acute edematous pancreatitis and maximal severity of this disease was observed 24 hours after induction of pancreatitis. Treatment with ghrelin reduced morphological signs of pancreatic damage such as pancreatic edema, leukocyte infiltration and vacuolization of acinar cells, and led to earlier regeneration of the pancreas. Also biochemical indexes of the severity of acute pancreatitis, serum activity of lipase and amylase were significantly reduced in animals treated with ghrelin. These effects were accompanied by an increase in the pancreatic DNA synthesis and a decrease in serum level of pro-inflammatory interleukin-1b. Administration of ghrelin improved pancreatic blood flow in rats with acute pancreatitis. We conclude that: (1) treatment with ghrelin exhibits therapeutic effect in caerulein-induced experimental acute pancreatitis; (2) this effect is related, at least in part, to the improvement of pancreatic blood flow, reduction in proinflammatory interleukin-1beta and stimulation of pancreatic cell proliferation.
Warzecha
Z
Z
Department of Physiology, Jagiellonian University Medical College, Cracow, Poland.
Ceranowicz
P
P
Dembinski
A
A
Cieszkowski
J
J
Kusnierz-Cabala
B
B
Tomaszewska
R
R
Kuwahara
A
A
Kato
I
I
D000208:Acute Disease; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D001786:Blood Glucose / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002108:Ceruletide / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D054439:Ghrelin / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors / Q000097:blood; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D010195:Pancreatitis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D015854:Up-Regulation / Q000187:drug effects
D001786:Blood Glucose; D054439:Ghrelin; D018836:Inflammation Mediators; D007328:Insulin; D053583:Interleukin-1beta; D002108:Ceruletide